Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas

Masjeed, Nayar Musfera Abdul; Khandeparkar, Siddhi Gaurish Sinai; Joshi, Avinash R; Kulkarni, M. L.; Pandya, Nidhi

doi:10.7860/jcdr/2017/28750.10475

Cited by 17 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study 100% of the cases of endometrial carcinoma showed positive expression of ER. However studies by Suthipintawong et al; [23] Suamchock et al; [24] Markova et al; [25] Sidonia et al; [26] Yu CG et al; [27] Pasam et al; [28] Musfera et al 29] ER expression was present in 76%, 59.3%, 79.3%,86.3%,44.7%, 68% and 60.7% of the cases respectively.…”

Section: Discussionmentioning

confidence: 99%

Histopathological and Immunohistochemical Study of Endometrial Lesions Obtained from D&C and Hysterectomy Specimens at a Tertiary Care Hospital

Bhattacharya

Jha²,

Agarwal³

et al. 2018

APALM

View full text Add to dashboard Cite

Background: Endometrial lesions are represented by a set of diversified disorders which has challenged clinicians for a long time. Due to its chances of progressing to malignant states, the condition needs prompt and focussed study, keeping clinical context in view. Methods: This 12-month (June 2016-May 2017) cross-sectional studyinvolved 100 specimens from dilatation and curettage (D & C) and hysterectomy specimens from female patientsaged ≥ 18 years who presented with complain of pelvic pain, abnormal uterine bleeding, dysmenorrhoea, pelvic mass and infertility. For all the specimens received,histopathological and immunohistochemical assessment was done. Results: Out of 100 cases of abnormal uterine bleeding 44 females showed physiological changes, 25 females showed benign lesions and 20 females had malignant lesions of endometrium. Out of 20 cases of endometrial carcinoma 50 % were well differentiated and 25% were moderately differentiated and 25% were poorly differentiated. Expression of Ki-67 was >35% in poorly differentiated carcinoma. Well differentiated carcinoma showed 80-85% positivity of ER, moderately differentiated showed 30-35% positivity and poorly differentiated carcinoma showed 6-12%. The association between benign and malignant endometrial lesion was found to be statistically significant with age-group, history of contraceptive use and chronic illnesses (p<0.05). Conclusion: Endometrial biopsy is one of the prompt tools in diagnosis and assessment of the benign and malignant diseases of endometrium. Immunohistochemical markers like ER (hormonal receptor) and Ki-67 (proliferative marker) play a major role in diagnosis, prognostication and therapeutic management of malignant cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Histopathological and Immunohistochemical Study of Endometrial Lesions Obtained from D&C and Hysterectomy Specimens at a Tertiary Care Hospital

Bhattacharya

Jha²,

Agarwal³

et al. 2018

APALM

View full text Add to dashboard Cite

show abstract

“…EGFR protein is normally expressed in normal glandular endometrium, and EGFR could play a dual role in endometrial carcinoma, such that high EGFR expression in type I carcinoma is associated with low grade and favorable outcomes, but in contrast, EGFR expression in type II carcinoma was associated with high grade and adverse clinical outcome. (14)(15)(16)(17) The p53 mutation in endometrial carcinoma is related to tumor survival and metastasis risk, (18) however, in the endometrioid adenocarcinoma it was observed p53 immunostaining only in papillary area of the tumor. At the present investigation in clear cells RCC p53 expression was negative ( Figure 2), but nevertheless p53 expression is considered rare in clear cells RCC, in relation to other types of renal carcinomas.…”

Section: Discussionmentioning

confidence: 98%

Expression of EGFR family and p53 in a patient with Synchronous Primary Endometrial Adenocarcinoma and Clear Cell Renal Carcinoma: a Case Report

Martins¹,

Souza²,

Ferreira³

et al. 2019

BJOncology

View full text Add to dashboard Cite

We present a case of a 69 year-old, non-obese, post-menopausal woman diagnosed with synchronous endometrial adenocarcinoma and renal cell carcinoma. Immunolocalization and expression of the EGFR, HER-2, HER-3, HER-4 and p53 proteins by immunohistochemistry (IHC) was performed to investigate synchronous expression of these proteins. The endometrial adenocarcinoma was a well-differentiated tumor, with discernable glandular structure with moderate mitotic index. IHC revealed weak HER-2, HER-3 and HER-4 staining of cell membranes in well-differentiated areas, and intense HER-2 and p53 staining in papillary areas. The renal cell carcinoma showed clear cell type, solid tumor, Fuhrman nuclear grade 2, presence of necrosis and hemorrhage. IHC revealed intense HER-2 and HER-4 staining of cell membranes, weak EGFR staining, and negative expression for HER-3 and p53 protein. In summary, overexpression of HER-2 and HER-4 may correlate with histological grade of the tumor and patient prognosis.

show abstract

“…For ki67 and p53 staining assessment, nuclear staining intensity was scored using three categories; mild, moderate, and strong. e staining ratio was scored as 0 for no staining, 1 for <10%, 2 for 10% to 50%, and 3 for >50% [13].…”

Section: Staining Scoringmentioning

confidence: 99%

“…ey describe a pattern which is not seen in normal tissue and is different from diffuse p16 positivity as seen in high-risk HPV positive cervical intraepithelial lesions [11]. Inoue [12] reported that endometrial metaplasia, in general, was a precursor of variant types of endometrial carcinomas, based on the p53, PCNA, and ki67 overexpression in EC and endometrial metaplasia and the fact that EC are often accompanied by adjacent metaplastic epithelium [13]. However, it is, for now, not a generally accepted view that endometrial metaplasia is a precursor of endometrial cancer.…”

Section: Introductionmentioning

confidence: 99%

Could Obesity be a Triggering Factor for Endometrial Tubal Metaplasia to be a Precancerous Lesion?

Elsaka

Zamzam

et al. 2020

Journal of Obesity

View full text Add to dashboard Cite

Background & Aims. Endometrial tubal metaplasia (ETM) is mostly described in conjunction with unopposed estrogen levels, and its association with endometrial hyperplasia and endometrial carcinoma (EC) is striking. Obesity is a risk factor for endometrial hyperplasia and EC development. The aim of this study is to investigate the impact of BMI and serum estradiol level on expression of PAX-2, H-TERT, P16, Ki-67, and P53 in studied ETM in reference to benign endometrium and EC. Methods. The study was conducted on the following groups: group (1) consists of 57 cases that had endometrial biopsies with histologically demonstrable ETM (typical or atypical) and all were subjected to serum estradiol levelling and body mass index (BMI) evaluation; group (2) had adjacent benign endometrial tissue as control; group (3) consists of 52 cases of conventional endometrial carcinoma and 16 serous carcinoma paraffin blocks which were collected and reevaluated. All included groups were immunostained for PAX-2, H-TERT, p16, ki67, and p53. Results. The relation between BMI and serum estradiol level in group 1 and PAX-2, H-TERT, P16, and p53 was statistically significant, while their relation with atypia and ki67 expression was insignificant. Twenty-three ETM cases (40.4%) out of group 1 were all (100%) obese, 87% had high serum estradiol level, and 73.9% were postmenopausal and had a similar immunohistochemical profile as EC cases (group 3). Conclusions. The presence of ETM regardless of the histologic atypia in obese postmenopausal patients with high serum estradiol level is an alarming sign. This implies that ETM might not be as benign as generally accepted, as under certain clinical conditions, it may turn into a potential premalignant lesion.

show abstract

Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas

Abstract: Introduction: Endometrial carcinoma is the second most common gynecologic malignancy in the developing countries. Endometrial Hyperplasia (EH) is a precursor to Endometrioid Adenocarcinoma (EMAC). A 23% of Atypical Hyperplasias (AEH) progress to EMAC.

Cited by 17 publications

References 14 publications

Histopathological and Immunohistochemical Study of Endometrial Lesions Obtained from D&C and Hysterectomy Specimens at a Tertiary Care Hospital

Histopathological and Immunohistochemical Study of Endometrial Lesions Obtained from D&C and Hysterectomy Specimens at a Tertiary Care Hospital

Expression of EGFR family and p53 in a patient with Synchronous Primary Endometrial Adenocarcinoma and Clear Cell Renal Carcinoma: a Case Report

Could Obesity be a Triggering Factor for Endometrial Tubal Metaplasia to be a Precancerous Lesion?

Contact Info

Product

Resources

About